Enasidenib (IDHIFA®, AG-221; Celgene Corporation, Summit, NJ, USA) is an oral inhibitor of mutant-IDH2 proteins approved in the United States for the treatment of adult patients with mutant-IDH2 relapsed or refractory (R/R) AML. The gene discussed is IDH2; the disease is acute myeloid leukemia.